Fitt Insider Sword scales AI care, Flo exposes perimenopause gaps, Life Biosciences tests longevity
Jan 29, 2026
A rapid roundup of health tech moves, including a major acquisition that expands AI care into Germany’s reimbursement system. A large study reveals U.S. women often miss perimenopause symptoms like fatigue, mood shifts, sleep and digestive changes. Coverage of the first FDA-cleared human trial using partial cellular reprogramming to target glaucoma and advance longevity research.
AI Snips
Chapters
Transcript
Episode notes
AI Care Expansion Through Strategic Acquisition
- Sword Health is scaling by acquiring Kaia Health for $285M to broaden its AI care platform into Germany and the U.S.
- The deal buys access to Germany's 70M+ digital health reimbursement pathway and folds Kaia's MSK and pulmonary users into Sword's platform.
Consolidation Builds Reimbursement Scale
- Sword has grown beyond MSK into mental health and pelvic health, reaching 500,000 members and 1,000 employer partners.
- The company is consolidating to build scale across reimbursement systems as AI-first care nears mainstream adoption.
U.S. Women Lag In Perimenopause Awareness
- Flo Health and Mayo Clinic surveyed over 17,000 women across 158 countries on perimenopause awareness.
- U.S. women lag behind peers in the U.K., Canada, and Australia in recognizing common perimenopause symptoms.